http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2347265-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ce92a4d2fdab0cc5440f710c3787f38 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D451-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D451-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D451-04 |
| filingDate | 2005-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2010-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e31837fa3a144c3a8f872b92561f8e33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f6dea4346e78e35e374f6fb99771634 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9161a4d55800ebde18b9d5377c17fdf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99f24b0f70c10da56700d3c7a5342020 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec81aa57d761965b09f3c5381046ac0f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3a45f5a62cd2e5acce4f09912d9aea7 |
| publicationDate | 2010-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2347265-T3 |
| titleOfInvention | INDAZOL-CARBOXAMIDA COMPOUNDS. |
| abstract | A compound of the formula (I): ** (See formula) ** R1 is hydrogen, halogen, hydroxy, C1-4 alkyl or C1-4 alkoxy; R2 is C3-4 alkyl or C3-6 cycloalkyl; R3 is hydroxy, C1-3 alkoxy, C1-4 alkyl substituted by hydroxy or -OC (O) NRaRb; R4 is hydrogen or C1-4 alkyl; W is chosen from (a) Y, said Y is chosen from -N (R8a) C (O) R9, -N (R8a) S (O) 2R10, -N (R8a) C (O) OR12, -N ( R8a) C (O) NR13R14 and N (R8a) S (O) 2NR13R14; and (b) a remainder of the formula (b): ** (See formula) ** in which: X is chosen from -N (R8) C (O) R9, -N (R8) S (O) 2R10 , -S (R11) O2, -N (R8) C (O) OR12, -N (R8) C (O) NR13R14, -N (R8) S (O) 2 NR13R14, -C (O) NR13R14, - OC (O) NR13R14, -C (O) OR12, -OR15, -NR8R16, cyano, -SR15, CF3, pyridinyl, pyrrolyl, pyrimidinyl, thiomorpholinyl, thiazolidinyl, 1,1-dioxo-isothiazolidinyl, imidazolyl, indolyl, tetrahydrofuranyl, pyrrolidinyl and piperidinyl, said pyrrolidinyl is optionally substituted by oxo and piperidinyl is optionally substituted by 1-3 halogens; R5 is hydrogen or C1-4 alkyl, said C1-4 alkyl is optionally substituted by hydroxy, C1-3 alkoxy or cyano; R6 and R7 are independently selected at each occurrence between hydrogen, hydroxy, halogen, cyano and C1-4 alkyl, said C1-4 alkyl is optionally substituted by 1-2 substituents chosen from hydroxy, C1-3 alkoxy, halogen and cyano; R8 and R8a are hydrogen or C1-4 alkyl; or R5 and R8, R5 and R6, or R6 and R8 together form a C2-5 alkylenyl said C2-5 alkylenyl is optionally substituted by hydroxy, halogen, C1-3 alkyl substituted by hydroxy, or C1-3 alkoxy, or R3 and R5 or R3 and R8a together form an -OCH2CH2-; or R5 and R6 together form a - (CH2) q-Q- (CH2) q, in which Q is oxygen or sulfur and q is independently the number 0, 1 or 2; or R7 and X together form a -NHC (O) NHC (O) - or -C (O) NHC (O) NH-; R9 is selected from hydrogen, furanyl, tetrahydrofuranyl, pyridinyl and C1-4alkyl, said C1-4alkyl is optionally substituted by hydroxy or by 1-3 halogens; R10 is selected from hydrogen, C1-4 alkyl, pyridinyl and imidazolyl, said C1-4 alkyl is optionally substituted by -S (O) 2Rc, C3-6 cycloalkyl, or by 1-3 halogens and imidazolyl is optionally substituted by C1 alkyl -3; or R8 and R10 together form a C3 alkylenyl; R11 is -NRaRb or C1-4 alkyl, said C1-4 alkyl is optionally substituted by 1-3 halogens; or R5 and R11 or R6 and R11 together form a C2-5 alkylenyl; R12 is C1-4 alkyl; R13 and R14 are independently hydrogen or C1-4 alkyl; R15 is hydrogen or C1-4 alkyl, said C1-4 alkyl is optionally substituted by hydroxy; or when X is -SR15, R5 and R15 together form a C1-4 alkylenyl; R16 is - (CH2) r-R17, where r is the number 0, 1, 2 or 3; and R17 is selected from hydrogen, hydroxy, C1-3alkyl, C1-3alkoxy, -C (O) NRaRb, -C (O) -morpholinyl, pyridinyl, pyrrolyl, pyrimidinyl, morpholinyl and tetrahydrofuranyl, said C1-3alkoxy is optionally substituted by hydroxy; with the proviso that if r is the number 0, R17 is chosen from hydrogen, C1-3 alkyl, pyridinyl and pyrimidinyl; and if r is number 1, R17 is hydrogen or R17 forms a carbon-carbon bond with the carbon atom of - (CH2) r-; R18 is -C (O) O-C1-3 alkyl, -S (O) 2-C1-3 alkyl or -C (O) -C1-3 alkyl; Ra, Rb and Rc are independently hydrogen or C1-3 alkyl; a is the number 0 or 1; and n is an integer 1, 2, 3, 4 or 5; with the proviso that if n is 1, X is -SR15, or X forms a carbon-carbon bond with the carbon atom carrying the substituents R6 and R7; or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. |
| priorityDate | 2004-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 369.